abstract: Blood sucking animals are a rich source of proteinase inhibitors mainly those that interfere in their host hemostatic systems. The tick @entity2 is an ectoparasite of @entity1 and other animals. The aims of this work were the purification and characterization of @entity4 proteinase inhibitors present in @entity2 larvae (RsTI). The inhibitors (RsTI) were isolated by affinity chromatography on trypsin- @entity5 and ion exchange chromatographies in Resource Q and Mono S columns. These RsTIs were separated in around 12 different protein peaks, when they showed molecular masses between 8 and 18 kDa, by @entity0 -PAGE. Purified RsTIs presented differences in the specificity for different @entity4 proteinases. RsTIQ2 was, better inhibitor than RsTIQ7 and RsTIS5 for neutrophil elastase, plasmin, and HuPK with dissociation constants (K(i)) of 1.3, 3.2, and 22 nM, respectively. Other inhibitors such as RsTIQ7, RsTIS3, and RsTIS5 also affected neutrophil elastase and plasmin with K(i) in the nM range. The RsTIQ2, RsTIQ7, and RsTIS5 @entity3 sequence data allowed classifying them as members of the Kunitz-type @entity4 proteinase inhibitor family, even though the RsTI role is still unknown. Our present results showed that @entity4 proteinase inhibitors from @entity2 are similar to inhibitors from Boophilus microplus other hard tick species, suggesting a similar role of these inhibitors in hard tick species and also as a potential tool to generate or improve vaccine against different ectoparasites with an unique antigen.

title: XXXX trypsin inhibitors present in the tick larvae: isolation, characterization, and partial primary structure determination.

answer: @entity2


abstract: BACKGROUND: Alefacept is a T cell-modulating biologic therapy for @entity1 that could affect @entity0 ' ability to mount immune responses. OBJECTIVE: This open-label, phase IV, multicenter study assessed the ability of adults with chronic @entity1 receiving alefacept to generate antibodies to a pneumococcal polysaccharide vaccine ( @entity2 ). METHODS: @entity0 were treated with a standard 12-week course of alefacept and administered the 23-valent @entity2 at week 6. Antipneumococcal antibodies were measured at baseline and weeks 6, 9, 12, and 33. The primary end point was the percentage of @entity0 with a 2-fold or greater increase from prevaccination (week 6) to 6 weeks postvaccination (week 12) in antibody titers to 2 or more of 5 designated PPV antigens. RESULTS: Of 43 @entity0 enrolled, 42 were included in the full analysis set, with 86% of @entity0 exhibiting a 2-fold or greater increase and 57% of @entity0 exhibiting a 4-fold or greater increase in antibody titers to 2 or more of 5 designated antigens from prevaccination to 6 weeks postvaccination. At 6 months postvaccination, 78% of @entity0 had a 2-fold or greater increase and 47% of @entity0 had a 4-fold or greater increase in antibody titers to 2 or more of the 5 designated antigens. There were statistically significant increases in mean antibody titers to all 23 antigens in @entity2 from prevaccination to 6 weeks postvaccination. LIMITATIONS: This was an open-label study with no comparator. CONCLUSIONS: Most @entity0 mounted immune responses to @entity2 ; increases in antibody titers in these @entity0 were consistent with those seen in healthy individuals.

title: Immune response to pneumococcal polysaccharide vaccine in adults with chronic XXXX treated with alefacept.

answer: @entity1


abstract: Using surviving @entity0 @entity1 , the influence of blood serum lipoproteins on cellular lysosomes was studied. Lipoproteins were isolated by the preparative isopicnic ultracentrifugation method. Apoproteins were separated by means of delipidation of suitable lipoprotein fractions. After preincubation of @entity1 in media with @entity3 ( @entity3 ), low and very low density lipoproteins (LDDLP, VLDLP), apo- @entity3 and apo-VLDLP, the rise of free acid hydrolase activities was seen. The stability of lysosomes in @entity4 solutions turned out to be low, and the tendency to lysosomal aggregation increased. Typical peribiliary localization of lysosomes in the cell remained unchanged. Following preincubation of @entity1 with @entity2 , @entity5 and VLDLP or LDLP, the rise of free lysosomal enzyme activity, greater aggregation and lysosome polymorphism and their less osmotic resistance took place. After liver slice preincubation with hormones and @entity3 , besides all of these changes, the lysosomal translocation to the nuclei was seen. When apoproteins, separately or together with hormones, were added, the same type of alteration of lysosomal membranes occurred. Our results suggest an importance of lipo (apo) proteins in the control of structure and functions of cellular lysosomal apparatus.

title: [Functional and ultrastructural lysosome changes in surviving XXXX liver sections as affected by blood serum lipoproteins].

answer: @entity0


abstract: The prognosis of adult @entity0 with relapsed @entity5 ( @entity5 ) remains poor. Recent studies in adolescents and young adults reported better outcomes when therapy was intensified. Based on hyper-CVAD ( @entity4 / @entity6 / @entity3 / @entity2 ) as a backbone, we designed an augmented version with intensified doses of @entity6 , @entity2 , and asparaginase ( @entity8 in the first 62 @entity0 and pegaspargase in the remainder) starting from course 1. Ninety @entity0 have been enrolled, with a median age of 34 years (range, 14-70 years). Most @entity0 (78%) had pre-B @entity5 and were in first salvage (76%), with a first remission duration of 12.6 months (range, 1-78 months). Ten @entity0 had primary refractory disease. Of 88 evaluable @entity0 , 41 (47%) achieved complete remission (CR), with a median time to CR of 29 days (range, 18-80 days). Eight @entity0 (9%) died within the first 30 days. Median CR duration, progression-free survival, and overall survival were 5, 6.2, and 6 months, respectively. Median overall survival of CR @entity0 was 10.2 months (range, 1.4-69.5+ months). Twenty-eight @entity0 (32%) proceeded to stem cell transplantation. @entity1 were frequent. Pegaspargase was equally effective and easier to administer than @entity8 . @entity7 may be suitable to be studied in younger adults with untreated @entity5 .

title: @entity7 based on dose-intensified @entity6 , @entity2 , and asparaginase in adult XXXX salvage therapy.

answer: @entity5


abstract: The prognosis of adult @entity0 with relapsed @entity5 ( @entity5 ) remains poor. Recent studies in adolescents and young adults reported better outcomes when therapy was intensified. Based on hyper-CVAD ( @entity4 / @entity6 / @entity3 / @entity2 ) as a backbone, we designed an augmented version with intensified doses of @entity6 , @entity2 , and asparaginase ( @entity8 in the first 62 @entity0 and pegaspargase in the remainder) starting from course 1. Ninety @entity0 have been enrolled, with a median age of 34 years (range, 14-70 years). Most @entity0 (78%) had pre-B @entity5 and were in first salvage (76%), with a first remission duration of 12.6 months (range, 1-78 months). Ten @entity0 had primary refractory disease. Of 88 evaluable @entity0 , 41 (47%) achieved complete remission (CR), with a median time to CR of 29 days (range, 18-80 days). Eight @entity0 (9%) died within the first 30 days. Median CR duration, progression-free survival, and overall survival were 5, 6.2, and 6 months, respectively. Median overall survival of CR @entity0 was 10.2 months (range, 1.4-69.5+ months). Twenty-eight @entity0 (32%) proceeded to stem cell transplantation. @entity1 were frequent. Pegaspargase was equally effective and easier to administer than @entity8 . @entity7 may be suitable to be studied in younger adults with untreated @entity5 .

title: @entity7 based on dose-intensified @entity6 , XXXX , and asparaginase in adult @entity5 salvage therapy.

answer: @entity2


abstract: The prognosis of adult @entity0 with relapsed @entity5 ( @entity5 ) remains poor. Recent studies in adolescents and young adults reported better outcomes when therapy was intensified. Based on hyper-CVAD ( @entity4 / @entity6 / @entity3 / @entity2 ) as a backbone, we designed an augmented version with intensified doses of @entity6 , @entity2 , and asparaginase ( @entity8 in the first 62 @entity0 and pegaspargase in the remainder) starting from course 1. Ninety @entity0 have been enrolled, with a median age of 34 years (range, 14-70 years). Most @entity0 (78%) had pre-B @entity5 and were in first salvage (76%), with a first remission duration of 12.6 months (range, 1-78 months). Ten @entity0 had primary refractory disease. Of 88 evaluable @entity0 , 41 (47%) achieved complete remission (CR), with a median time to CR of 29 days (range, 18-80 days). Eight @entity0 (9%) died within the first 30 days. Median CR duration, progression-free survival, and overall survival were 5, 6.2, and 6 months, respectively. Median overall survival of CR @entity0 was 10.2 months (range, 1.4-69.5+ months). Twenty-eight @entity0 (32%) proceeded to stem cell transplantation. @entity1 were frequent. Pegaspargase was equally effective and easier to administer than @entity8 . @entity7 may be suitable to be studied in younger adults with untreated @entity5 .

title: @entity7 based on dose-intensified XXXX , @entity2 , and asparaginase in adult @entity5 salvage therapy.

answer: @entity6


abstract: The prognosis of adult @entity0 with relapsed @entity5 ( @entity5 ) remains poor. Recent studies in adolescents and young adults reported better outcomes when therapy was intensified. Based on hyper-CVAD ( @entity4 / @entity6 / @entity3 / @entity2 ) as a backbone, we designed an augmented version with intensified doses of @entity6 , @entity2 , and asparaginase ( @entity8 in the first 62 @entity0 and pegaspargase in the remainder) starting from course 1. Ninety @entity0 have been enrolled, with a median age of 34 years (range, 14-70 years). Most @entity0 (78%) had pre-B @entity5 and were in first salvage (76%), with a first remission duration of 12.6 months (range, 1-78 months). Ten @entity0 had primary refractory disease. Of 88 evaluable @entity0 , 41 (47%) achieved complete remission (CR), with a median time to CR of 29 days (range, 18-80 days). Eight @entity0 (9%) died within the first 30 days. Median CR duration, progression-free survival, and overall survival were 5, 6.2, and 6 months, respectively. Median overall survival of CR @entity0 was 10.2 months (range, 1.4-69.5+ months). Twenty-eight @entity0 (32%) proceeded to stem cell transplantation. @entity1 were frequent. Pegaspargase was equally effective and easier to administer than @entity8 . @entity7 may be suitable to be studied in younger adults with untreated @entity5 .

title: XXXX based on dose-intensified @entity6 , @entity2 , and asparaginase in adult @entity5 salvage therapy.

answer: @entity7


abstract: Atacicept, a specific inhibitor of BLys and APRIL, was used in a phase I study for 14 @entity0 with @entity1 ( @entity1 ) and 4 with Waldenstr  m's @entity2 (WM). They received 1 cycle of 5 once-weekly s.c. injections, followed by an extension if in stable disease or in response. The maximum tolerated dose was not identified. Of 11 @entity0 with @entity1 who completed initial treatment, 5 @entity0 were progression-free after cycle 1 and 4 @entity0 were progression-free after extended therapy. Of 4 @entity0 with WM, 3 @entity0 were progression-free after cycle 1. Polyclonal immunoglobulin isotypes and total B cells were reduced. Plasma concentrations of soluble CD 138 decreased. Biological effect was more pronounced in WM. Of the 16 @entity0 tested at baseline, 13 had measurable levels of free APRIL (>= 25 ng/mL). In this small series, no correlations were apparent between baseline levels of free APRIL and biological or clinical response criteria.

title: Phase I study of atacicept in relapsed/refractory multiple @entity1 ( XXXX ) and Waldenstr  m's @entity2 .

answer: @entity1


abstract: Atacicept, a specific inhibitor of BLys and APRIL, was used in a phase I study for 14 @entity0 with @entity1 ( @entity1 ) and 4 with Waldenstr  m's @entity2 (WM). They received 1 cycle of 5 once-weekly s.c. injections, followed by an extension if in stable disease or in response. The maximum tolerated dose was not identified. Of 11 @entity0 with @entity1 who completed initial treatment, 5 @entity0 were progression-free after cycle 1 and 4 @entity0 were progression-free after extended therapy. Of 4 @entity0 with WM, 3 @entity0 were progression-free after cycle 1. Polyclonal immunoglobulin isotypes and total B cells were reduced. Plasma concentrations of soluble CD 138 decreased. Biological effect was more pronounced in WM. Of the 16 @entity0 tested at baseline, 13 had measurable levels of free APRIL (>= 25 ng/mL). In this small series, no correlations were apparent between baseline levels of free APRIL and biological or clinical response criteria.

title: Phase I study of atacicept in relapsed/refractory multiple XXXX ( @entity1 ) and Waldenstr  m's @entity2 .

answer: @entity1


abstract: Atacicept, a specific inhibitor of BLys and APRIL, was used in a phase I study for 14 @entity0 with @entity1 ( @entity1 ) and 4 with Waldenstr  m's @entity2 (WM). They received 1 cycle of 5 once-weekly s.c. injections, followed by an extension if in stable disease or in response. The maximum tolerated dose was not identified. Of 11 @entity0 with @entity1 who completed initial treatment, 5 @entity0 were progression-free after cycle 1 and 4 @entity0 were progression-free after extended therapy. Of 4 @entity0 with WM, 3 @entity0 were progression-free after cycle 1. Polyclonal immunoglobulin isotypes and total B cells were reduced. Plasma concentrations of soluble CD 138 decreased. Biological effect was more pronounced in WM. Of the 16 @entity0 tested at baseline, 13 had measurable levels of free APRIL (>= 25 ng/mL). In this small series, no correlations were apparent between baseline levels of free APRIL and biological or clinical response criteria.

title: Phase I study of atacicept in relapsed/refractory multiple @entity1 ( @entity1 ) and Waldenstr  m's XXXX .

answer: @entity2


abstract: Microvascular rarefaction following an episode of @entity3 ( @entity3 ) is associated with @entity0 . The mechanisms contributing to microvascular rarefaction are not well-understood, although disruption in local angioregulatory substances is thought to contribute. @entity5 is an endopeptidase important in modifying the extracellular matrix (ECM) and remodeling the vasculature. We examined the role of @entity5 gene deletion on microvascular rarefaction in a rodent model of @entity2 @entity3 . @entity5 -null @entity1 and background control (FVB/NJ) @entity1 were subjected to bilateral renal artery clamping for 20 min followed by reperfusion for 14, 28, or 56 days. Serum @entity4 level in @entity5 -null @entity1 24 h after injury [1.4 (SD 0.8) mg/dl] was not significantly different from FVB/NJ @entity1 [1.5 (SD 0.6) mg/dl]. Four weeks after @entity2 , FVB/NJ @entity1 demonstrated a 30-40% loss of microvascular density compared with sham-operated (SO) @entity1 . In contrast, microvascular density was not significantly different in the @entity5 -null @entity1 at this time following injury compared with SO @entity1 . FVB/NJ @entity1 had a 50% decrease in tissue @entity6 ( @entity6 ) 2 wk after @entity2 insult compared with SO @entity1 . A significant difference in @entity6 was not observed in @entity5 -null @entity1 compared with SO @entity1 . There was no significant difference in the liberation of angioinhibitory fragments from the ECM between @entity5 -null @entity1 and FVB/NJ @entity1 following @entity2 . In conclusion, @entity5 deletion stabilizes microvascular density following @entity2 @entity3 in part by preserving tissue @entity6 levels.

title: XXXX gene deletion mitigates microvascular loss in a model of @entity3 .

answer: @entity5


abstract: Microvascular rarefaction following an episode of @entity3 ( @entity3 ) is associated with @entity0 . The mechanisms contributing to microvascular rarefaction are not well-understood, although disruption in local angioregulatory substances is thought to contribute. @entity5 is an endopeptidase important in modifying the extracellular matrix (ECM) and remodeling the vasculature. We examined the role of @entity5 gene deletion on microvascular rarefaction in a rodent model of @entity2 @entity3 . @entity5 -null @entity1 and background control (FVB/NJ) @entity1 were subjected to bilateral renal artery clamping for 20 min followed by reperfusion for 14, 28, or 56 days. Serum @entity4 level in @entity5 -null @entity1 24 h after injury [1.4 (SD 0.8) mg/dl] was not significantly different from FVB/NJ @entity1 [1.5 (SD 0.6) mg/dl]. Four weeks after @entity2 , FVB/NJ @entity1 demonstrated a 30-40% loss of microvascular density compared with sham-operated (SO) @entity1 . In contrast, microvascular density was not significantly different in the @entity5 -null @entity1 at this time following injury compared with SO @entity1 . FVB/NJ @entity1 had a 50% decrease in tissue @entity6 ( @entity6 ) 2 wk after @entity2 insult compared with SO @entity1 . A significant difference in @entity6 was not observed in @entity5 -null @entity1 compared with SO @entity1 . There was no significant difference in the liberation of angioinhibitory fragments from the ECM between @entity5 -null @entity1 and FVB/NJ @entity1 following @entity2 . In conclusion, @entity5 deletion stabilizes microvascular density following @entity2 @entity3 in part by preserving tissue @entity6 levels.

title: @entity5 gene deletion mitigates microvascular loss in a model of XXXX .

answer: @entity3


abstract: BACKGROUND: Endoscopic sphincterotomy (ES) is an established procedure in treatment of diseases of the biliary tract; management of serious complications such as @entity7 remains controversial. Because mortality is high if @entity2 is inadequately treated by no use of operative means, many surgeons advocate routine operative repair and drainage upon diagnosis. In surveys of large experiences, however, the majority @entity0 initially were treated non-surgically, and the majority recovered. OBJECTIVE: To evaluate our experience with non-surgical management in @entity0 with @entity7 after ES. @entity0 AND METHODS: Retrospective chart review from January 1991 to December 2000 identified 12 instances of @entity7 . We reviewed endoscopic cholangiopancreatography (ERCP) findings, diagnostic methods, time to diagnosis, methods of management, length of @entity0 stay, and outcome. RESULTS: Twelve @entity0 with diagnosis of @entity6 (5) papillary stenoses (4) and @entity4 (3) had @entity7 among 1,510 ES performed (0.79%). In all cases during ES, retroperitoneal air on fluoroscopic examinations was observed and diagnosis was made. One @entity0 was managed initially by surgery and @entity1 occurred due to @entity3 . Eleven @entity0 were treated conservatively with nasogastric aspiration, none by mouth intravenous fluids, antibiotics, and @entity5 analog without mortality. Median length of stay was 6.7 days. CONCLUSIONS: @entity7 after ES may be treated conservatively with success if identified during ES or early stage. Early diagnosis of @entity7 is essential for optimum outcome.

title: [Conservative management of XXXX following endoscopic sphincterotomy of papilla of Vater].

answer: @entity7


abstract: BACKGROUND: @entity7 ( @entity7 ), a marker of @entity1 , is one of the major cytokines released during joint replacement. In the orthopedic @entity0 population, high levels have been linked to many adverse effects including acute @entity6 , postoperative mental status changes, and @entity2 . We looked to assess the efficacy of low-dose @entity3 on the postinflammatory response as measured by @entity7 in @entity0 undergoing bilateral total knee replacement (BTKR). The role of @entity3 has never been evaluated before in that setting. METHODS: Double-blind, randomized, placebo-controlled study of 30 @entity0 undergoing BTKR. The study was powered in order to detect at least a 25% decrease in @entity7 from control. @entity8 (100 mg) or placebo was given at 2 doses 8 hrs apart to the study and control group respectively. Clinical outcome was assessed as well. RESULTS: Levels of @entity7 were 40% lower in the study group by 10 hrs (P = 0.0037) but were similar to the control group at 24 hrs. Greater hemodynamic stability was noted in the study group with fewer episodes of @entity5 postoperatively (P = 0.031). Range of motion gained on discharge was also greatest in the study group (P = 0.049). Absence of @entity4 and normal wound healing were noted in all @entity0 . CONCLUSIONS: The use of @entity8 significantly decreased the inflammatory response in @entity0 undergoing BTKR as measured by @entity7 production. Further studies looking at clinical implications of such findings in a larger @entity0 population and with a longer course of @entity3 are warranted.

title: Use of low-dose XXXX in decreasing cytokine release during bilateral total knee replacement.

answer: @entity3


abstract: BACKGROUND: Australia has the highest incidence of @entity1 in the world. The majority of lesions occur in the head and neck with metastases to the parotid gland lymph nodes reflecting an uncommon, but aggressive, manifestation. Parotidectomy +/- neck dissection followed by adjuvant radiotherapy should be considered as best practice. METHODS: Between 1983 and 2000, seventy-four @entity0 were treated for metastatic @entity1 to the parotid with surgery and adjuvant radiotherapy at Westmead Hospital, Sydney. Relevant data were extracted from @entity0 files and a prospectively maintained database. Patterns of relapse and outcome were analysed. RESULTS: Median age at diagnosis was 65 years (34-93 years) in 63 @entity0 and 11 @entity0 . Median follow-up duration was 41 months (12-188 months). All @entity0 underwent parotidectomy with 52 undergoing a simultaneous neck dissection. Twelve @entity0 required sacrifice of the facial nerve (4) or one or more branches (8). All received adjuvant radiotherapy to the parotid region with 56 also receiving radiotherapy to the ipsilateral neck. Despite treatment, 24% developed locoregional recurrence, with a median time to relapse of 7.5 months. The most common site for recurrence was the treated parotid region and upper neck. Most relapsed @entity0 died. No variable independently predicted for locoregional recurrence on multivariate analysis. The 5-year absolute and cause-specific survival rates were 58% and 72%, respectively. CONCLUSION: Parotid gland lymph node metastases from @entity1 are associated with a high rate of recurrence and cause-specific mortality despite current best practice (surgery and high dose adjuvant radiotherapy). The role of more aggressive surgery, altered fractionation or chemotherapy to enhance locoregional control remains unclear.

title: Metastatic XXXX to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome.

answer: @entity1


abstract: The first empirical use of alpha(1)-adrenoceptor antagonists in urology occurred about 25 years ago in @entity0 with lower urinary tract symptoms (LUTS) suggestive of @entity1 ( @entity1 ), or LUTS/ @entity1 . Today, many randomized, controlled trials have provided evidence for the efficacy and tolerability of alpha(1)-adrenoceptor antagonists in LUTS/ @entity1 , and they are the most frequently used initial treatment option for this cause of LUTS. For many years, alpha(1)-adrenoceptor antagonists have also been used empirically in other types of lower urinary tract dysfunction (LUTD), such as @entity3 ( @entity3 ) and neurogenic LUTD (NLUTD). Several investigators have shown that alpha(1)-adrenoceptor antagonists may be useful in @entity0 with @entity3 . This was recently confirmed by a 6-week, double-blind, placebo-controlled pilot study evaluating the efficacy and safety of @entity4 in 58 @entity3 @entity0 . Further well-designed and -powered research into the use of alpha(1)-adrenoceptor antagonists in @entity0 with @entity3 is currently ongoing. Several small-scale predominantly open-label studies have suggested that alpha(1)-adrenoceptor antagonists may be of benefit in @entity0 with NLUTD. Data from 2 recent large-scale studies with @entity4 in @entity0 with NLUTD caused by suprasacral @entity2 suggest that long-term @entity4 treatment improves bladder storage and emptying and also reduces symptoms of @entity5 . @entity4 has also shown promise in ameliorating (early) storage symptoms and urinary retention associated with transurethral microwave thermotherapy, external-beam radiotherapy, and brachytherapy. In @entity1 @entity0 presenting with the ultimate form of LUTS-acute urinary retention-treatment with @entity4 before catheter removal results in a higher success rate of catheter-free voiding. Finally, it seems that alpha(1)-adrenoceptor antagonists may reduce the occurrence of urinary retention after (general) surgery. We can therefore conclude that alpha(1)-adrenoceptor antagonists, such as @entity4 , may be useful for treating @entity0 with LUTS beyond @entity1 .

title: The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond XXXX .

answer: @entity1


abstract: The possibility that the putative transmitter @entity1 ( @entity1 ) is involved in the mediation of long latency to onset raphe-spinal inhibition of sympathetic preganglionic neurones was investigated in anaesthetized @entity0 by stimulating sites located in nucleus raphe pallidus and obscurus and recording sympathetic discharge in T3 or T10 white rami evoked either reflexively or by intraspinal stimulation at cervical level. Several putative @entity1 antagonists were administered intravenously (i.v.) or topically to the spinal cord. In 7 @entity0 @entity5 (LSD) in a dose range 25-50 microgram/kg i.v. or 0.6 microgram topically, reversibly reduced the raphe spinal inhibition by 40-100%. Topical application was more effective than i.v. administration. In 5 @entity0 stimulating within the ventromedial reticular formation at sites unlikely to involved @entity1 neurones produced a short latency to onset inhibition which was unaffected by LSD. @entity2 , @entity3 and @entity4 depressed sympathetic discharge in the absence of brain stimulation in @entity0 with CNS intact and in unanaesthetized decerebrate spinal @entity0 . The results are discussed in the light of the known actions of the putative @entity1 antagonists.

title: Inhibition of sympathetic activity by stimulating in the raphe nuclei and the role of XXXX in this effect.

answer: @entity1


abstract: BACKGROUND: Excessive @entity1 use is associated with a variety of negative health outcomes, including @entity4 , @entity3 , and @entity5 . OBJECTIVE: To determine the 2-year risk of gastrointestinal-related hospitalization and new-onset @entity2 based on @entity1 screening scores. DESIGN: Retrospective cohort study. @entity0 : Male (N = 215, 924) and female (N = 9,168) outpatients who returned mailed questionnaires and were followed for 24 months. MEASUREMENTS: @entity1 Use Disorder Identification Test-Consumption Questionnaire (AUDIT-C), a validated three-item @entity1 screening questionnaire (0-12 points). RESULTS: Two-year risk of hospitalization with a @entity2 was increased in @entity0 with AUDIT-C scores of 5-8 and 9-12 (OR 1.54, 95% CI = 1.27-1.86; and OR 3.27; 95% CI = 2.62-4.09 respectively), and @entity0 with AUDIT-C scores of 9-12 (OR 6.84, 95% CI = 1.85 - 25.37). @entity0 with AUDIT-C scores of 5-8 and 9-12 had increased risk of new-onset @entity4 (OR 1.49, 95% CI = 1.30-1.71; and OR 2.82, 95% CI = 2.38-3.34 respectively), and new-onset of @entity3 (OR 1.28, 95% CI = 1.05-1.57; and OR 2.14, 95% CI = 1.54-2.97 respectively). Two-year risk of new-onset @entity5 in @entity0 with AUDIT -C scores 9-12 was also increased (OR 2.14; 95% CI = 1.54-2.97). CONCLUSIONS: Excessive @entity1 use as determined by AUDIT-C is associated with 2-year increased risk of gastrointestinal-related hospitalization in @entity0 and @entity0 and new-onset @entity4 , @entity3 , and @entity5 in @entity0 . These results provide risk information that clinicians can use in evidence-based conversations with @entity0 about their @entity1 consumption.

title: XXXX screening scores and the risk of new-onset @entity2 or related hospitalization.

answer: @entity1


abstract: BACKGROUND: Excessive @entity1 use is associated with a variety of negative health outcomes, including @entity4 , @entity3 , and @entity5 . OBJECTIVE: To determine the 2-year risk of gastrointestinal-related hospitalization and new-onset @entity2 based on @entity1 screening scores. DESIGN: Retrospective cohort study. @entity0 : Male (N = 215, 924) and female (N = 9,168) outpatients who returned mailed questionnaires and were followed for 24 months. MEASUREMENTS: @entity1 Use Disorder Identification Test-Consumption Questionnaire (AUDIT-C), a validated three-item @entity1 screening questionnaire (0-12 points). RESULTS: Two-year risk of hospitalization with a @entity2 was increased in @entity0 with AUDIT-C scores of 5-8 and 9-12 (OR 1.54, 95% CI = 1.27-1.86; and OR 3.27; 95% CI = 2.62-4.09 respectively), and @entity0 with AUDIT-C scores of 9-12 (OR 6.84, 95% CI = 1.85 - 25.37). @entity0 with AUDIT-C scores of 5-8 and 9-12 had increased risk of new-onset @entity4 (OR 1.49, 95% CI = 1.30-1.71; and OR 2.82, 95% CI = 2.38-3.34 respectively), and new-onset of @entity3 (OR 1.28, 95% CI = 1.05-1.57; and OR 2.14, 95% CI = 1.54-2.97 respectively). Two-year risk of new-onset @entity5 in @entity0 with AUDIT -C scores 9-12 was also increased (OR 2.14; 95% CI = 1.54-2.97). CONCLUSIONS: Excessive @entity1 use as determined by AUDIT-C is associated with 2-year increased risk of gastrointestinal-related hospitalization in @entity0 and @entity0 and new-onset @entity4 , @entity3 , and @entity5 in @entity0 . These results provide risk information that clinicians can use in evidence-based conversations with @entity0 about their @entity1 consumption.

title: @entity1 screening scores and the risk of new-onset XXXX or related hospitalization.

answer: @entity2


abstract: @entity3 are uncommon @entity1 arising from mesenchymal tissue, accounting for approximately 10% of soft-tissue @entity3 and less than 1% of all @entity1 . The most frequent subtypes of @entity3 are @entity4 . Total surgical extirpation appears the only chance for @entity0 cure since medical therapies have shown little efficacy. We have analyzed our series of 32 @entity5 that undergone surgical resection and with at least 5 years of follow-up. We have included 21 @entity0 who underwent a complete resection (R0) and 6 @entity0 who underwent an incomplete resection (R1). However, the operation's goal was a complete @entity1 resection with @entity1 -free resection margins. The 5-year survival was 85.7% when we performed a R0 resection, while it was 33.3% when we performed a R1 resection with a significant statistical difference (p = 0.02). Surgery is the gold standard for treatment of @entity4 . Despite advances in diagnostic modalities, surgical techniques and the adoption of more aggressive procedure, such disease still has a propensity for local recurrence, even after an apparent complete resection. Therefore, locoregional recurrence remains the main cause of @entity2 in @entity0 with a @entity5 . Moreover when the @entity1 recurs locally, the treatment of choice is to remove the recurrence. Our experience shows that a complete resection of primary lesions and further resection of recurrences early detected with CT examination could improve the overall survival of @entity0 with @entity5 . Moreover in our series, the @entity0 who undergo R1 resection had a worse prognosis.

title: Management of high-grade XXXX : personal experience.

answer: @entity5


abstract: The endothelium regulates vascular tone through the release of vasodilating and vasoconstricting substances. The most important of these vasodilating substances is @entity8 (NO), which is also vascular protective and inhibits inflammation, oxidation, vascular smooth muscle cell proliferation, and migration. Damage to the endothelium causes @entity4 with impaired release of NO and loss of its antiatherogenic protection. Traditional risk factors for @entity6 , including @entity0 , @entity9 , @entity1 , and low levels of high-density lipoprotein @entity2 , are associated with @entity4 and thus promote the atherogenic process. More recently, insulin resistance in the absence of overt @entity0 or the @entity3 has been associated with @entity4 . This association provides evidence that the @entity7 process may actually begin earlier in the spectrum of insulin resistance, ultimately resulting in a progression of the @entity3 to @entity11 and then to type 2 @entity0 . Aggressive treatment of @entity10 and @entity1 , even before the onset of type 2 @entity0 , would appear prudent in decreasing the progression of the @entity7 process. The @entity13 are @entity12 agonists that improve @entity5 and lipid metabolism. These agents have recently been shown to improve endothelial function in the early stages of insulin resistance. Results from ongoing trials with @entity13 will reveal whether they will also reduce cardiovascular end points.

title: Role of XXXX in insulin resistance.

answer: @entity4


abstract: OBJECTIVES: This study was designed to clarify and resolve the clinical profile of older @entity0 with @entity2 ( @entity2 ). BACKGROUND: Adverse consequences of @entity2 such as @entity1 and incapacitating symptoms have been emphasized for the young and middle-aged. METHODS: Long-term outcome of @entity2 was assessed in a community-based cohort not subject to tertiary center referral bias. RESULTS: Of 312 @entity0 , 73 (23%) achieved normal life expectancy (> or =75 years; range to 96); 44 (14%) were > or =80 years old. Most @entity0 > or =75 years (47; 64%) experienced no or only mild limiting symptoms and lived virtually their entire lives with few @entity2 -related clinical consequences; 26 @entity0 (36%) experienced severe progressive symptoms. In elderly @entity0 with @entity2 , diagnosis and symptom onset were considerably delayed to 74 +/- 8 and 70 +/- 11 years, respectively. For @entity0 > or =50 years at diagnosis, the probability of survival for 5, 10, and 15 years was 85 +/- 3%, 74 +/- 4%, and 57 +/- 6%, respectively, and did not significantly differ from a matched general population (p = 0.20). @entity0 > or =75 years were predominantly @entity0 , and had less marked wall thickness and more frequently showed basal outflow obstruction > or =30 mm Hg (compared with those <75 years; p < 0.01 and 0.001, respectively). CONCLUSIONS: @entity2 is frequently well tolerated and compatible with normal life expectancy, and may remain clinically dormant for long periods of time with symptoms and initial diagnosis deferred until late in life. These observations afford a measure of reassurance to many @entity0 with @entity2 , a disease for which clinical course is often unfavorable and unpredictable.

title: Clinical course of XXXX with survival to advanced age.

answer: @entity2


abstract: BACKGROUND: @entity6 is a potent inhibitor of @entity2 growth in vitro. To examine whether synthetic oral @entity6 can be tolerated by @entity0 with recurrent @entity2 ( @entity4 ) and to investigate its efficacy against these @entity1 , the authors undertook an open-label, sequential dose escalation/de-escalation tolerance study. METHODS: @entity0 with documented recurrent or progressive @entity2 who had received standard radiation therapy with or without chemotherapy were included. @entity0 were excluded for previous treatment with agents known to contain @entity6 or treatment within 30 days with medications known to cause photosensitivity. Enrolled @entity0 were given gradually increasing dosages of oral synthetic @entity6 (0.05-0.50 mg/kg) for up to 3 months if no @entity3 was observed, and @entity0 response to treatment was noted. The @entity0 were examined each month and underwent magnetic resonance imaging to evaluate @entity1 status at 3 months. RESULTS: Synthetic @entity6 administered orally appeared to provide stabilization or a slight (<50%) decrease in @entity1 volume (coded as stable disease) at 3 months for 7 of 42 @entity0 (17%) and produced a @entity1 reduction >50% (partial response) in 2 @entity0 (5%). Seventeen @entity0 (40%) survived for 3 months on daily synthetic @entity6 at dose levels of 0.33    0.070 mg/kg daily. The mean maximum tolerated dose was 0.40    0.098 mg/kg daily. Twelve @entity0 continued on @entity6 therapy beyond 3 months. The median survival was 26 weeks (Kaplan-Meier method). CONCLUSIONS: The results of this study indicated that synthetic, oral @entity6 is well tolerated in this @entity0 group. The response results were comparable to those reported from other studies of salvage therapies for recurrent @entity5 .

title: A phase 1/2 study of orally administered synthetic @entity6 for treatment of recurrent XXXX .

answer: @entity2


abstract: BACKGROUND: @entity6 is a potent inhibitor of @entity2 growth in vitro. To examine whether synthetic oral @entity6 can be tolerated by @entity0 with recurrent @entity2 ( @entity4 ) and to investigate its efficacy against these @entity1 , the authors undertook an open-label, sequential dose escalation/de-escalation tolerance study. METHODS: @entity0 with documented recurrent or progressive @entity2 who had received standard radiation therapy with or without chemotherapy were included. @entity0 were excluded for previous treatment with agents known to contain @entity6 or treatment within 30 days with medications known to cause photosensitivity. Enrolled @entity0 were given gradually increasing dosages of oral synthetic @entity6 (0.05-0.50 mg/kg) for up to 3 months if no @entity3 was observed, and @entity0 response to treatment was noted. The @entity0 were examined each month and underwent magnetic resonance imaging to evaluate @entity1 status at 3 months. RESULTS: Synthetic @entity6 administered orally appeared to provide stabilization or a slight (<50%) decrease in @entity1 volume (coded as stable disease) at 3 months for 7 of 42 @entity0 (17%) and produced a @entity1 reduction >50% (partial response) in 2 @entity0 (5%). Seventeen @entity0 (40%) survived for 3 months on daily synthetic @entity6 at dose levels of 0.33    0.070 mg/kg daily. The mean maximum tolerated dose was 0.40    0.098 mg/kg daily. Twelve @entity0 continued on @entity6 therapy beyond 3 months. The median survival was 26 weeks (Kaplan-Meier method). CONCLUSIONS: The results of this study indicated that synthetic, oral @entity6 is well tolerated in this @entity0 group. The response results were comparable to those reported from other studies of salvage therapies for recurrent @entity5 .

title: A phase 1/2 study of orally administered synthetic XXXX for treatment of recurrent @entity2 .

answer: @entity6


abstract: @entity2 undergoes a reversible morphological transition from single @entity1 cells to pseudohyphal and hyphal filaments. In this organism, @entity0 -dependent protein kinase (PKA), coded by two catalytic subunits ( @entity5 and @entity3 ) and one regulatory subunit ( @entity4 ), mediates basic cellular processes, such as the @entity1 -to-hypha transition and cell cycle regulation. It is known that both Tpk isoforms play positive roles in vegetative growth and filamentation, although distinct roles have been found in virulence, stress response and glycogen storage. However, little is known regarding the participation of Tpk1p and/or Tpk2p in pseudohyphal development. This point was addressed using several @entity2 PKA mutants having heterozygous or homozygous deletions of @entity5 and/or @entity3 in different @entity4 genetic backgrounds. We observed that under hypha-only inducing conditions, all @entity4 heterozygous strains shifted growth toward pseudohyphal morphology; however, the pseudohypha:hypha ratio was higher in strains devoid of @entity3 . Under pseudohypha-only inducing conditions, strains lacking @entity3 were prone to develop short and branched pseudohyphae. In @entity3 /\/ @entity3 /\ strains, biofilm architecture was markedly less dense, composed of short pseudohyphae and blastospores with reduced adhesion ability to abiotic material, suggesting a significant defect in cell adherence. Immunolabelling assays showed a decreased expression of adhesins Als1p and Als3p only in the @entity3 /\/ @entity3 /\ strain. Complementation of this mutant with a wild-type copy of @entity3 restored all the altered functions: pseudohyphae elongation, biofilm composition, cell aggregation and adhesins expression. Our study suggests that the Tpk2p isoform may be part of a mechanism underlying not only polarized pseudohyphal morphogenesis but also cell adherence.

title: XXXX Tpk1p and Tpk2p isoforms differentially regulate pseudohyphal development, biofilm structure, cell aggregation and adhesins expression.

answer: @entity2


abstract: INTRODUCTION: @entity8 is a rare @entity1 of smooth muscle origin. It has been reported in many anatomical sites, but it usually affects limbs. It's recurrence rate is slow but it's quite difficult to make diagnosis. CASE REPORT: The study describes the case of a 53-year-old @entity0 , with a subcutaneous, large @entity8 of the right clavicular region. The @entity0 had a @entity3 , slow-growing mass, measuring more than 20 mm. The mass had a relatively homogeneous, hypoechoic-echo texture, with a small amount of posterior acoustic enhancement. No diagnosis was made and the @entity0 underwent surgery for a suspected leyomioma. After surgery a hard, round-shaped @entity1 , measuring approximately 43 x 32 mm of diameter was found with histological features of leyomioma. DISCUSSION: The case has an unusual clinical presentation, for the uncommon localization and size of the mass. US imaging and histopathologic features are reported. The rarity of @entity8 makes diagnosis difficult and frequently delayed. Differential diagnosis includes @entity4 , @entity1 , @entity5 , @entity9 , @entity7 , and @entity2 . CONCLUSIONS: This report highlights that @entity6 , even of large dimension, must be included in the differential diagnosis of @entity3 , subcutaneous masses.

title: A large XXXX or an infected sebaceous cyst of the chest? A case report.

answer: @entity8


abstract: The clinical and pathologic data from two cases of @entity4 with systemic @entity1 , and 101 previously reported cases were evaluated to define better the clinical presentation and natural history. @entity0 ranged in age from six months to 48 years, with a mean of 13 years; two thirds of the @entity0 were male. Ventricular shunts had been inserted in 20% of the @entity0 . Systemic @entity1 occurred on an average of two years after the diagnosis of the @entity2 in @entity0 without shunts, but only 1.3 years in @entity0 with shunts. Fifty-nine percent of the @entity0 were known to have experienced recurrence or spread of @entity4 within the central nervous system by the time systemic @entity1 appeared. Ninety percent showed radiologic evidence of bone @entity1 , of which 60% were osteoblastic. Bones most frequently involved were pelvis, femur and vertebrae; @entity3 was the most common initial symptom. At autopsy, lymph node @entity1 were found in 65% and liver @entity1 were found in 28% of all cases in addition to bone @entity1 in 82%. Lung @entity1 occurred in 9% of the @entity0 without shunts, compared with 30% of @entity0 with shunts. The average survival was seven months after the appearance of systemic @entity1 for @entity0 both with and without shunts. Approximately 5% of @entity0 with @entity4 may be expected to develop systemic @entity1 . This development is associated with increased morbidity and a shortened life expectancy.

title: Systemic @entity1 from XXXX : report of two cases and review of the literature.

answer: @entity4


abstract: The clinical and pathologic data from two cases of @entity4 with systemic @entity1 , and 101 previously reported cases were evaluated to define better the clinical presentation and natural history. @entity0 ranged in age from six months to 48 years, with a mean of 13 years; two thirds of the @entity0 were male. Ventricular shunts had been inserted in 20% of the @entity0 . Systemic @entity1 occurred on an average of two years after the diagnosis of the @entity2 in @entity0 without shunts, but only 1.3 years in @entity0 with shunts. Fifty-nine percent of the @entity0 were known to have experienced recurrence or spread of @entity4 within the central nervous system by the time systemic @entity1 appeared. Ninety percent showed radiologic evidence of bone @entity1 , of which 60% were osteoblastic. Bones most frequently involved were pelvis, femur and vertebrae; @entity3 was the most common initial symptom. At autopsy, lymph node @entity1 were found in 65% and liver @entity1 were found in 28% of all cases in addition to bone @entity1 in 82%. Lung @entity1 occurred in 9% of the @entity0 without shunts, compared with 30% of @entity0 with shunts. The average survival was seven months after the appearance of systemic @entity1 for @entity0 both with and without shunts. Approximately 5% of @entity0 with @entity4 may be expected to develop systemic @entity1 . This development is associated with increased morbidity and a shortened life expectancy.

title: Systemic XXXX from @entity4 : report of two cases and review of the literature.

answer: @entity1


abstract: @entity2 peroxidase (GPx) is an important member of cellular enzymatic antioxidant system, which may be involved in pathogen defense of host. In the present study, a @entity3 -dependent @entity2 peroxidase (MmeGPx) gene from clam @entity4 was cloned and analyzed. The MmeGPx gene was composed of two introns of 723  bp and 238  bp and an open reading frame (ORF) of 711  bp. The ORF encodes a protein of 237 @entity1 with a putative @entity6 residue encoded by an unusual stop codon. MmeGPx shares a higher level of similarity with @entity0 @entity7 than with other @entity0 GPx isozymes. The level of MmeGPx mRNA roughly paralleled GPx enzyme activity in different tissues except in gills, with the highest mRNA expression and enzyme activity occurring in hepatopancreas. MmeGPx mRNA expressions were detected in different larval stages and the results showed that MmeGPx mRNA increased significantly in pediveliger stage, which may be a response to oxidative stress. After challenge of clam with a @entity5 -related bacterium (MM21), the expression of MmeGPx was significantly up-regulated at 6  h and 12  h in hepatopancreas, which suggested that MmeGPx may be involved in the immune response to MM21 infection. To better understand its role in the immunity of clam, the expression of MmeGPx in hepatopancreas was compared between a selected Vibrio-resistant population and a control population after immersion challenge with MM21. Early up-regulation of MmeGPx was observed in the resistant population. These results suggested that MmeGPx might be involved in maintaining the redox state of immune system, and the early immune response to pathogen infection may help the clam against pathogen infection.

title: Molecular characterization of a @entity2 peroxidase gene and its expression in the selected Vibrio-resistant population of the clam XXXX .

answer: @entity4


abstract: @entity2 peroxidase (GPx) is an important member of cellular enzymatic antioxidant system, which may be involved in pathogen defense of host. In the present study, a @entity3 -dependent @entity2 peroxidase (MmeGPx) gene from clam @entity4 was cloned and analyzed. The MmeGPx gene was composed of two introns of 723  bp and 238  bp and an open reading frame (ORF) of 711  bp. The ORF encodes a protein of 237 @entity1 with a putative @entity6 residue encoded by an unusual stop codon. MmeGPx shares a higher level of similarity with @entity0 @entity7 than with other @entity0 GPx isozymes. The level of MmeGPx mRNA roughly paralleled GPx enzyme activity in different tissues except in gills, with the highest mRNA expression and enzyme activity occurring in hepatopancreas. MmeGPx mRNA expressions were detected in different larval stages and the results showed that MmeGPx mRNA increased significantly in pediveliger stage, which may be a response to oxidative stress. After challenge of clam with a @entity5 -related bacterium (MM21), the expression of MmeGPx was significantly up-regulated at 6  h and 12  h in hepatopancreas, which suggested that MmeGPx may be involved in the immune response to MM21 infection. To better understand its role in the immunity of clam, the expression of MmeGPx in hepatopancreas was compared between a selected Vibrio-resistant population and a control population after immersion challenge with MM21. Early up-regulation of MmeGPx was observed in the resistant population. These results suggested that MmeGPx might be involved in maintaining the redox state of immune system, and the early immune response to pathogen infection may help the clam against pathogen infection.

title: Molecular characterization of a XXXX peroxidase gene and its expression in the selected Vibrio-resistant population of the clam @entity4 .

answer: @entity2


abstract: Nine plasma cell @entity4 @entity0 spontaneously developed histologically proven @entity6 ( @entity6 ) limited predominantly to the gastrointestinal tract within 1 month of initial @entity1 ( @entity1 ) using high-dose melphalan conditioning. All recipients responded promptly to systemic and nonabsorbable oral corticosteroid therapy. All @entity0 previously received systemic therapy with @entity8 , @entity9 , or @entity5 before @entity1 . Using enzymatic amplification staining-enhanced flow cytometry, we evaluated expression of selected transcription regulators, pathway molecules, and surface receptors on samples of the infused hematopoietic cell grafts. We demonstrated significantly enhanced expression of @entity10 , @entity11 , and @entity3 on @entity7 (+) hematopoietic progenitor cells of affected @entity0 compared with 42 unaffected @entity1 controls. These 3 overexpressed markers have not been previously implicated in autologous @entity6 . Although we did not specifically evaluate T cells, we postulate that exposure over time to the various immunomodulating therapies used for induction treatment affected not only the @entity7 (+) cells but also T cells or relevant T cell subpopulations capable of mediating @entity6 . After infusion, the affected hematopoietic progenitor cells then encounter a host that has been further altered by the high-dose melphalan preparative regimen; such a situation leads to the syndrome. These surface markers could be used to develop a model to predict development of this syndrome. Autologous @entity6 potentially is a serious complication of @entity1 and should be considered in plasma cell @entity4 @entity0 with otherwise unexplained gastrointestinal symptoms in the immediate post- @entity1 period. Prompt recognition of this condition and protracted treatment with nonabsorbable or systemic @entity2 or the combination may lead to resolution.

title: Spontaneous XXXX in plasma cell @entity4 autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.

answer: @entity6


abstract: Nine plasma cell @entity4 @entity0 spontaneously developed histologically proven @entity6 ( @entity6 ) limited predominantly to the gastrointestinal tract within 1 month of initial @entity1 ( @entity1 ) using high-dose melphalan conditioning. All recipients responded promptly to systemic and nonabsorbable oral corticosteroid therapy. All @entity0 previously received systemic therapy with @entity8 , @entity9 , or @entity5 before @entity1 . Using enzymatic amplification staining-enhanced flow cytometry, we evaluated expression of selected transcription regulators, pathway molecules, and surface receptors on samples of the infused hematopoietic cell grafts. We demonstrated significantly enhanced expression of @entity10 , @entity11 , and @entity3 on @entity7 (+) hematopoietic progenitor cells of affected @entity0 compared with 42 unaffected @entity1 controls. These 3 overexpressed markers have not been previously implicated in autologous @entity6 . Although we did not specifically evaluate T cells, we postulate that exposure over time to the various immunomodulating therapies used for induction treatment affected not only the @entity7 (+) cells but also T cells or relevant T cell subpopulations capable of mediating @entity6 . After infusion, the affected hematopoietic progenitor cells then encounter a host that has been further altered by the high-dose melphalan preparative regimen; such a situation leads to the syndrome. These surface markers could be used to develop a model to predict development of this syndrome. Autologous @entity6 potentially is a serious complication of @entity1 and should be considered in plasma cell @entity4 @entity0 with otherwise unexplained gastrointestinal symptoms in the immediate post- @entity1 period. Prompt recognition of this condition and protracted treatment with nonabsorbable or systemic @entity2 or the combination may lead to resolution.

title: Spontaneous @entity6 in plasma cell XXXX autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.

answer: @entity4


abstract: @entity6 ( @entity6 ) are synthetic peptides exerting GH-dependent or GH-independent effects via GH secretagogue receptor on many organs, including the heart. The underlying mechanisms of the cardiotropic properties of @entity6 are poorly understood. This study investigates these effects of four @entity6 in isolated perfused heart preparations and isolated neonatal and adult ventricular myocytes. The @entity1 response of cardiocytes to @entity6 was visualized using confocal microscopy. All tested @entity6 facilitated both ventricular contraction and relaxation in a dose-dependent manner, moderately decreasing coronary flow, but not modifying heart rate. @entity6 induced a biphasic increase in intracellular free @entity0 of the cardiocytes, consisting of a transient phase (phase 1), followed by a plateau phase (phase 2). Phase 1 was abolished by pretreatment with @entity5 , a @entity0 - @entity2 triphosphatase inhibitor of the sarcoplasmic reticulum. The phase 2 response was eliminated by removing extracellular free @entity0 , by @entity4 , a voltage-gated @entity0 channel blocker, or by 24-h pretreatment with @entity3 , down-regulating protein kinase C. In isolated (denervated) heart, @entity6 have a direct cardiotropic, without chronotropic, effect. @entity6 elevate myocardial intracellular free @entity0 through activating @entity0 influx via voltage-gated @entity0 channels and triggering @entity0 release from @entity5 -sensitive intracellular @entity0 stores. Protein kinase C mediates the @entity6 -induced @entity0 influx, but not @entity0 release. These finding support a number of roles for @entity6 in the cardiovascular system.

title: The positive inotropic and XXXX -mobilizing effects of growth hormone-releasing peptides on rat heart.

answer: @entity1


abstract: Neurosteroids are synthesized de novo in the brain, and the cerebellar Purkinje cell is a major site for neurosteroid formation. We have demonstrated that the Purkinje cell possesses intranuclear receptor for @entity5 and actively produces @entity5 de novo from @entity2 only during @entity0 neonatal life, when cerebellar cortical formation occurs dramatically. We have further demonstrated that @entity5 promotes dendritic growth, spinogenesis, and synaptogenesis via its receptor in this neuron in the neonate. On the other hand, @entity3 may also play an important role in the process of cerebellar cortical formation, because the neonatal @entity0 Purkinje cell possesses @entity3 receptor ( @entity6 . However, @entity3 formation in the neonatal cerebellum is still unclear. In this study, we therefore analyzed the biosynthesis and action of @entity3 in Purkinje cells during neonatal life. RT-PCR-Southern and in situ hybridization analyses showed that Purkinje cells expressed the key enzyme of @entity3 formation, cytochrome P450 aromatase, in neonatal @entity0 . A specific enzyme immunoassay for @entity1 further indicated that cerebellar @entity1 concentrations in the neonate were significantly higher than those in the prepuberty and adult. Both in vitro and in vivo studies with newborn @entity0 showed that @entity1 promoted dose-dependent dendritic growth of Purkinje cells. @entity1 also increased the density of Purkinje dendritic spines. These effects were inhibited by the ER antagonist @entity4 . These results suggest that @entity1 in the developing Purkinje cell promotes dendritic growth and spinogenesis via @entity6 in this neuron. @entity1 as well as @entity5 may contribute to the growth of Purkinje cells during the cerebellar cortical formation.

title: Dendritic growth and spine formation in response to XXXX in the developing Purkinje cell.

answer: @entity3


abstract: Controversy regarding functional reorganization in the adult brain remains. To investigate whether neuroplasticity is present in adults with @entity3 , we examined the pattern of cerebral @entity1 metabolism on @entity2 brain PET images of postlingually deaf @entity0 by comparing the auditory cortical activation pattern with those of age- and sex-matched healthy control subjects. We also correlated the cerebral @entity1 metabolism in deaf @entity0 with the duration of @entity3 using statistical parametric mapping. METHODS: In the resting state (eye closed, ears unoccluded in a dark and quiet environment), @entity2 brain PET scans were performed on 9 postlingually deaf @entity0 and 9 age- and sex-matched healthy volunteers. Significant increases and decreases of regional cerebral metabolism in the @entity0 group were estimated by comparing their PET images with those of the healthy volunteers using t statistics at every voxel. To reveal regions in which metabolism was significantly correlated with the duration of @entity3 , the general linear model with the duration of @entity3 as a covariate was tested at each voxel. RESULTS: When we compared @entity2 brain PET images of postlingually deaf @entity0 with those of age- and sex-matched healthy control subjects by performing a t test at every voxel, the @entity1 metabolism of deaf @entity0 was significantly (P < 0.001) lower than that of the control subjects in both anterior cingulate gyri (Brodmann area 24 [BA24]) and superior temporal cortices (BA41, BA42) and in the right parahippocampal gyrus. No area showed a significant increase of metabolism in deaf @entity0 with the same threshold. When we correlated @entity1 metabolism of deaf @entity0 with the duration of @entity3 after total deprivation of hearing capability using a general linear model with the duration of @entity3 as a covariate at every voxel, metabolism in both anterior cingulate gyri (BA24) and superior temporal cortices (BA41, BA42) showed a significant (P < 0.005) positive correlation with the duration of @entity3 . CONCLUSION: This study suggests that plasticity is present in adult brains of postlingually deaf @entity0 . In the mature brain, auditory deprivation decreased neuronal activity transiently in primary auditory and auditory-related cortices, and, over time, functional reorganization likely takes place in the auditory cortex. Plasticity was prominent in superior temporal and anterior cingulate gyri in the sensory-deprived mature brain and militated against postimplantation improvement in @entity0 with cochlear implants.

title: PET evidence of neuroplasticity in adult auditory cortex of XXXX .

answer: @entity3


abstract: NKT cells play important roles in the regulation of diverse immune responses. Therefore, chemokine receptor expression and chemotactic responses of @entity0 TCRalphabeta NKT cells were examined to define their homing potential. Most NKT cells stained for the chemokine receptor @entity8 , while >90% of @entity12 i-positive and approximately 50% of @entity12 i-negative NKT cells expressed @entity14 via an enhanced green fluorescent protein reporter construct. @entity3 expression was higher on @entity12 i-negative than @entity12 i-positive NKT cells. In spleen only, subsets of @entity12 i-positive and -negative NKT cells also expressed @entity13 . NKT cell subsets migrated in response to ligands for the inflammatory chemokine receptors @entity8 (monokine induced by @entity5 ) and @entity14 ( @entity11 ), and regulatory chemokine receptors @entity7 ( @entity6 ( @entity6 )/CC ligand (CCL)21), @entity3 (stromal cell-derived factor-1/ @entity9 ), and @entity13 (B cell-attracting chemokine-1/ @entity10 ); but not to ligands for other chemokine receptors. Two NKT cell subsets migrated in response to the lymphoid homing chemokine @entity6 /CCL21: @entity1 (-) Valpha14i-negative NKT cells that were @entity2 (high) and enriched for expression of @entity15 (consistent with the phenotype of most NKT cells found in peripheral lymph nodes); and immature @entity12 i-positive cells lacking @entity4 and @entity2 . Mature @entity4 (+) Valpha14i-positive NKT cells did not migrate to @entity6 /CCL21. @entity10 / @entity10 , which mediates homing to B cell zones, elicited migration of @entity12 i-positive and -negative NKT cells in the spleen. These cells were primarily @entity1 (+) or @entity1 (-)CD8(-) and were enriched for Ly49C/I, but not @entity15 . Low levels of chemotaxis to @entity11 were only detected in @entity12 i-positive NKT cell subsets. Our results identify subsets of NKT cells with distinct homing and localization patterns, suggesting that these populations play specialized roles in immunological processes in vivo.

title: Differential chemokine responses and homing patterns of XXXX TCR alpha beta NKT cell subsets.

answer: @entity0


abstract: PURPOSE: The goal of this study was to evaluate the incidence and clinical features of @entity2 ( @entity2 ). METHODS: We retrospectively performed chart reviews of 22 @entity0 with @entity2 who were diagnosed and treated in the university medical center from 1998 to 2009 inclusively. RESULTS: @entity2 among ovarian pathology in our hospital were detected in 22 @entity0 (1.79%). The mean age was 50 years, range (20-90). Post surgical FIGO staging was Stage I = 86.4%, and Stage II = 13.6%. The most common histologic subtype was mucinous (59%). Five @entity0 (22.7%) had a unilocular cyst at ultrasonography. Conservative surgery was performed in 31.8%. One @entity0 of them had normal spontaneous delivery after term pregnancy. Two @entity0 had a recurrence. One @entity0 with recurrent disease underwent transformation to @entity1 and died 35 months after the initial diagnosis. CONCLUSION: Clinicians should warn @entity0 about the early relapse of @entity2 and these @entity0 may need careful follow-up due to the possibility of recurrences.

title: Clinical analysis of XXXX .

answer: @entity2


abstract: @entity5 and @entity7 associated with @entity6 may be due to equinovalgus and/or metatarsus primus adductus or combinations of these. Occasionally the condition occurs in equinovarus feet. @entity5 " is usually due to a weak @entity4 longus, overpull of the anterior tibial muscle on the first metatarsal and @entity1 or contracture of the @entity2 longus or brevis. A weak peroneus longus muscle has not caused this deformity. The condition is usually predictable in the growing @entity0 if all factors related to gait, collagen stability and foot alignment are observed. Treatment includes soft-tissue and bone realignment. Release of the adductor hallucis, lateral collateral ligaments of the metatarsophalangeal joint, plication of the medial capsule and of the abductor hallucis and centralization of the @entity4 longus will realign the first ray. The @entity2 longus is transferred to athe @entity4 longus proximal to the metatarsophalangeal joint and the anterior tibial tendon is transferred to the second metatarsal. An osteotomy at the base of the first metatarsal and at the base of the proximal phalanx will realign the skeleton. Twenty-six great toes in 16 @entity0 have been observed for two to 20 years. The correction has been maintained without arthrodesis of the metatarsophalangeal joint except where @entity3 occurred. Once the pattern of deformity is evident, progression is unrelenting and treatment is indicated in order to prevent @entity3 .

title: XXXX and @entity7 associated with cerebral palsy: analysis and treatment.

answer: @entity5


abstract: @entity5 and @entity7 associated with @entity6 may be due to equinovalgus and/or metatarsus primus adductus or combinations of these. Occasionally the condition occurs in equinovarus feet. @entity5 " is usually due to a weak @entity4 longus, overpull of the anterior tibial muscle on the first metatarsal and @entity1 or contracture of the @entity2 longus or brevis. A weak peroneus longus muscle has not caused this deformity. The condition is usually predictable in the growing @entity0 if all factors related to gait, collagen stability and foot alignment are observed. Treatment includes soft-tissue and bone realignment. Release of the adductor hallucis, lateral collateral ligaments of the metatarsophalangeal joint, plication of the medial capsule and of the abductor hallucis and centralization of the @entity4 longus will realign the first ray. The @entity2 longus is transferred to athe @entity4 longus proximal to the metatarsophalangeal joint and the anterior tibial tendon is transferred to the second metatarsal. An osteotomy at the base of the first metatarsal and at the base of the proximal phalanx will realign the skeleton. Twenty-six great toes in 16 @entity0 have been observed for two to 20 years. The correction has been maintained without arthrodesis of the metatarsophalangeal joint except where @entity3 occurred. Once the pattern of deformity is evident, progression is unrelenting and treatment is indicated in order to prevent @entity3 .

title: @entity5 and XXXX associated with cerebral palsy: analysis and treatment.

answer: @entity7


abstract: @entity3 are defined as a generalized state associated with a significantly increased risk of @entity0 . For the oral and perioral region, @entity2 , @entity8 ( @entity8 ), @entity6 ( @entity6 ), syphilis, @entity9 , @entity5 as well as @entity7 play a role as @entity3 . The number of published cases of oral or perioral malignant transformation for some of these diseases is small. In addition, @entity4 associated with syphilis are of historical interest, although publications in the 1990s still reported positive serology of syphilis and @entity1 of the tongue. @entity8 is still controversially discussed as to its premalignant nature. Transformation rates have been reported between 0% and 5.6%. Recent prospective studies have revealed that possibly oral lichenoid reactions (OLR) are more likely to form the basis of malignant transformation as compared to the classic @entity8 . The differentiation between @entity8 and OLR is difficult both from clinical and histopathological aspects. The second most important @entity3 is @entity6 , which is caused by betel quid chewing. @entity6 is most prevalent in South and Southeast Asia. The transformation rate is as high as 7.6% making @entity6 one of the most important @entity3 of the oral region.

title: [Oral XXXX --an overview].

answer: @entity3


abstract: BACKGROUND: The proportion of dental causes of @entity2 is estimated between 10% and 40%. The mechanisms are manifold and originate from the close relation of the side teeth and the maxillary sinus. In the past, the transantral approach was commonly used by maxillofacial surgeons as their first choice. @entity0 AND METHODS: Between 01/1999 and 10/2001 38 @entity0 underwent endoscopic surgery controlled via the fossa canina. Apart from the mandatory treatment of the dental focus and the mucosal pathologies, a fenestration to the middle meatus of the nose was performed in 7 cases. RESULTS AND CONCLUSION: The dental medical history, @entity5 , CT scans in coronary plane, endoscopic findings, and histology showed the commonly "silent" course of dental @entity3 . Typical findings in CT scans are unilateral basal maxillary opacities adjacent to the @entity4 . In 20% of the cases there was also a blockade of the infundibulum. All @entity0 were reexamined 6-12 months postoperatively. The @entity0 are free of symptoms, but sometimes suffer from @entity1 . An exact diagnosis and the clear separation of rhinogenic causes are vital points for the therapy of dental @entity3 . In cases of unilateral @entity3 , a comprehensive investigation by the maxillofacial surgeon should be recommended. Video-assisted endoscopic sinus revision is preferable to the transantral approach and is especially suitable for the treatment of mucosal @entity6 , the removal of foreign bodies, endoscopically controlled resections of apical roots, elevations of the sinus floor, and dental implants. If the ethmoidal infundibulum and maxillary ostium are open, no fenestration is needed. In cases of blockade, fenestration to the middle nose canal is indicated.

title: [Video-assisted endoscopic sinus revision for treatment of chronic, unilateral odontogenic XXXX ].

answer: @entity2


abstract: @entity2 or American @entity0 @entity5 , is a @entity4 due to @entity3 , which is endemic in Latin America. The parasite is transmitted by haematophagous vectors from reduviidae family. In some @entity0 , the parasite is responsible for severe complications such as cardiac manifestations, @entity1 . Imported @entity2 by immigration in non-endemic countries poses the threat of the infection transmission by blood transfusion. In order to prevent this risk, the French Blood Services (EFS) introduced systematic screening of at-risk blood donors for anti-T. cruzi antibodies, in May 2007. The concerned donors are @entity0 originating from an endemic area, donors with mothers originating from such an area and individuals who had lived in or travelled to endemic areas. Donors were screened with two different Elisas simultaneously: one Elisa using purified parasite lysate antigens and the second one composed of recombinant antigens. Positive results and discrepant results were further assayed with an immunofluorescence assay. A seroprevalence assay was performed in the 17 French blood centres after an 18-month testing period from May 2007 to December 2008. During this period 4,637,479 million donations were collected. Out of these 163,740 donations were tested (3.5%). The prevalence of anti-T. cruzi antibodies was one in 32,800 donations. Five positive donors were identified. All of them were originating from endemic areas. A rate of 0.85% indeterminate results was found. Screening strategy revision was decided to reduce the number of donors unnecessarily deferred.

title: [ XXXX and blood transfusion: an emerging issue in non-endemic countries].

answer: @entity2


abstract: OBJECTIVE: To compare vocational interests as a function of sex and race among @entity0 with recent @entity1 ( @entity1 ), because previous research used almost exclusively white @entity0 . Limited research from nearly 2 decades ago suggested @entity1 selectively occurs to @entity0 whose vocational interests are consistent with the Realistic theme of the Holland typology, indicative of a preference for activities and occupations requiring physical strength and dexterity. DESIGN: The Strong Interest Inventory (SII) was completed an average of 50 days after @entity1 onset. SETTING: Data were collected at a specialty hospital and analyzed at a medical university. @entity0 : Adults with traumatic @entity1 (N=500) were assessed during inpatient rehabilitation. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: The SII, a 317-item measure of vocational interests. RESULTS: Although the findings for white @entity0 were consistent with elevation of the Realistic theme when compared with the reference group, the interests of @entity0 and black @entity0 were substantially different. @entity0 scored highest on Social, Enterprising, and Conventional themes compared with the reference group. Black @entity0 reported significantly higher elevations than whites on 5 themes (all except Realistic), with elevations on the Social, Enterprising, and Conventional themes exceeding standardized norms. The Artistic and Investigative themes were least descriptive of the overall sample. CONCLUSIONS: Rehabilitation professionals should be aware of likely differences in patterns of vocational interests as a function of race and sex, and use vocational interests as a means of facilitating postinjury adaptation.

title: Vocational interests after recent XXXX : comparisons related to sex and race.

answer: @entity1


abstract: BACKGROUND: @entity4 (CP) embryotoxicity was documented in several studies on different experimental models. We investigate quantitatively the relationship between the embryotoxic effect of CP and the disturbance of the cell-cycle using flow cytometry. METHODS: @entity5 embryos on Days 2-4 were treated with 0.5, 1, 2, 4, 8, and 16 microg doses of pure substance of CP by intraamniotic or subgerminal administration routes. Cell-cycle analysis was carried out in the brain, limb buds, hearts, and facial outgrowths dissected from the embryos 6 hr after administration. Samples of nuclear suspensions were obtained by enzymatic and mechanical disintegration of solid tissues in collagenase-dispase, followed by detergent and RNA-ase mediated cytolysis. Nuclei were stained by @entity6 . RESULTS: A dose-dependent increase of S-phase cells followed by decrement of G2M cell compartment was observed. The significant block of S-phase cells, however, was not always associated with @entity3 . The degree of cell-cycle disturbance was expressed more readily by the ratio G2M/S that demonstrated consistently the threshold character of both teratogenic and lethal effects. CONCLUSION: CP-induced @entity0 manifested by dose-dependent disturbance of cell-cycle resulted in an overall @entity2 of proliferation activity clearly associated with the occurrence of @entity3 and @entity1 . Although a non-significant @entity2 of mitotic activity appeared sufficient to produce @entity3 on Day 2, remarkably deeper disturbance was needed to interfere with the development of the embryos in more advanced stages. Changes in proliferation rate appear to be a primary and most important event in teratogenesis induced by general toxic agents.

title: Cell-cycle alterations underlie @entity4 -induced teratogenesis in the XXXX embryo.

answer: @entity5


abstract: BACKGROUND: @entity4 (CP) embryotoxicity was documented in several studies on different experimental models. We investigate quantitatively the relationship between the embryotoxic effect of CP and the disturbance of the cell-cycle using flow cytometry. METHODS: @entity5 embryos on Days 2-4 were treated with 0.5, 1, 2, 4, 8, and 16 microg doses of pure substance of CP by intraamniotic or subgerminal administration routes. Cell-cycle analysis was carried out in the brain, limb buds, hearts, and facial outgrowths dissected from the embryos 6 hr after administration. Samples of nuclear suspensions were obtained by enzymatic and mechanical disintegration of solid tissues in collagenase-dispase, followed by detergent and RNA-ase mediated cytolysis. Nuclei were stained by @entity6 . RESULTS: A dose-dependent increase of S-phase cells followed by decrement of G2M cell compartment was observed. The significant block of S-phase cells, however, was not always associated with @entity3 . The degree of cell-cycle disturbance was expressed more readily by the ratio G2M/S that demonstrated consistently the threshold character of both teratogenic and lethal effects. CONCLUSION: CP-induced @entity0 manifested by dose-dependent disturbance of cell-cycle resulted in an overall @entity2 of proliferation activity clearly associated with the occurrence of @entity3 and @entity1 . Although a non-significant @entity2 of mitotic activity appeared sufficient to produce @entity3 on Day 2, remarkably deeper disturbance was needed to interfere with the development of the embryos in more advanced stages. Changes in proliferation rate appear to be a primary and most important event in teratogenesis induced by general toxic agents.

title: Cell-cycle alterations underlie XXXX -induced teratogenesis in the @entity5 embryo.

answer: @entity4


abstract: OBJECTIVE: @entity7 ( @entity7 ) stimulates cell motility via binding its receptor ( @entity6 ) and @entity6 is engaged in @entity3 cell motility and the @entity6 gene expression level may define a more @entity4 phenotype. In this study, we investigated the expression of @entity6 in @entity1 cells and revealed its roles in the cell motility of a @entity3 . We detected @entity6 expression in tissue specimens from @entity0 with @entity5 ( @entity5 ) and assessed their clinical characteristics. METHODS: Using reverse transcription-polymerase chain reaction (RT-PCR) analyses and phagokinetic assay, we studied the correlation between the level of @entity6 gene expression and cell motility. We quantified the expression of @entity6 in 51 @entity0 with @entity5 to investigate the relationship between @entity6 expression and clinicopathologic factors and prognosis. RESULTS: We found that @entity1 cell lines with higher @entity6 gene expression tended to have larger cell motility than those with lower @entity6 gene expression. The @entity6 gene expression was significantly associated with lymph node @entity2 , and stage. The overall survival rate for @entity0 with a high level of @entity6 gene expression with @entity3 was significantly worse than for those individuals whose @entity3 had low @entity6 expression. Furthermore, @entity6 expression was significantly related to survival by multivariate analysis. CONCLUSION: These data indicate that @entity7 -R may contribute to @entity3 progression and @entity6 gene expression can serve as a useful prognostic marker in @entity5 .

title: @entity7 -receptor gene expression in XXXX .

answer: @entity1


abstract: OBJECTIVE: @entity7 ( @entity7 ) stimulates cell motility via binding its receptor ( @entity6 ) and @entity6 is engaged in @entity3 cell motility and the @entity6 gene expression level may define a more @entity4 phenotype. In this study, we investigated the expression of @entity6 in @entity1 cells and revealed its roles in the cell motility of a @entity3 . We detected @entity6 expression in tissue specimens from @entity0 with @entity5 ( @entity5 ) and assessed their clinical characteristics. METHODS: Using reverse transcription-polymerase chain reaction (RT-PCR) analyses and phagokinetic assay, we studied the correlation between the level of @entity6 gene expression and cell motility. We quantified the expression of @entity6 in 51 @entity0 with @entity5 to investigate the relationship between @entity6 expression and clinicopathologic factors and prognosis. RESULTS: We found that @entity1 cell lines with higher @entity6 gene expression tended to have larger cell motility than those with lower @entity6 gene expression. The @entity6 gene expression was significantly associated with lymph node @entity2 , and stage. The overall survival rate for @entity0 with a high level of @entity6 gene expression with @entity3 was significantly worse than for those individuals whose @entity3 had low @entity6 expression. Furthermore, @entity6 expression was significantly related to survival by multivariate analysis. CONCLUSION: These data indicate that @entity7 -R may contribute to @entity3 progression and @entity6 gene expression can serve as a useful prognostic marker in @entity5 .

title: XXXX -receptor gene expression in @entity1 .

answer: @entity7


abstract: INTRODUCTION: This article describes a case series outlining the experience and results of the retroperitoneal minimally invasive @entity5 (MIPN) procedure performed by, or done under the supervision of, a single surgeon. METHODS: All data of the @entity0 who underwent MIPN from 2006 to 2008 were entered into a prospectively maintained, computerized database. RESULTS: A total of 93 MIPN procedures were performed on 32 @entity0 . All @entity0 had severe acute @entity5 . The median number of MIPN procedures per @entity0 was 3. Only 6 @entity0 needed intensive care unit (ICU) admission after MIPN. There were 15 complications, which included @entity3 requiring transfusion (n = 3), bowel fistulae (n = 7), @entity6 events (n = 2) and acute @entity4 (n = 3). Four @entity0 died after the procedure (13%); 1 died of @entity2 in spite of the MIPN. Four @entity0 developed @entity7 within the follow-up period of 2 years. Three of these @entity0 required intervention. CONCLUSION: This case series demonstrates that MIPN can be performed with acceptable morbidity and mortality and with good end results. The ICU dependency after the procedure is minimal. As seen in this series, multiple MIPNs may be needed to eradicate the @entity1 satisfactorily. and IAP.

title: Minimally invasive retroperitoneal XXXX .

answer: @entity5


abstract: Replication-competent adenovirus type 5 ( @entity6 ) vectors promise to be more efficient gene delivery vehicles than their replication-deficient counterparts, and chimeric @entity6 vectors that are capable of targeting @entity5 are more effective than @entity6 vectors with native fibers. Although several strategies have been used to improve gene transduction and oncolysis, either by modifying their tropism or enhancing their replication capacity, some @entity0 cells are still relatively refractory to infection by chimeric @entity6 . The oncolytic effects of the vectors are apparent in certain @entity0 but not in others. Here, we report the biological and oncolytic profiles of a replication-competent adenovirus 11p vector (RCAd11pGFP) in @entity4 cells. @entity5 was abundantly expressed in all cells studied; however, the transduction efficiency of RCAd11pGFP varied. RCAd11pGFP efficiently transduced HT-29, HCT-8, and LS174T cells, but it transduced T84 cells, derived from a @entity4 metastasis in the lung, less efficiently. Interestingly, RCAd11p replicated more rapidly in the T84 cells than in HCT-8 and LS174T cells and as rapidly as in HT-29 cells. Cell @entity2 and proliferation assays indicated that RCAd11pGFP had the highest cell-killing activities in HT29 and T84 cells, the latter of which also expressed the highest levels of glycoproteins of the @entity3 embryonic antigen (CEA) family. In vivo experiments showed significant growth inhibition of T84 and HT-29 @entity0 in xenograft @entity1 treated with either RCAd11pGFP or Ad11pwt compared to untreated controls. Thus, RCAd11pGFP has a potent cytotoxic effect on @entity4 cells.

title: Transduction and oncolytic profile of a potent replication-competent adenovirus 11p vector (RCAd11pGFP) in XXXX cells.

answer: @entity4


abstract: BACKGROUND AND PURPOSE: The goal of this study was to prospectively assess outcome and cost for poor-grade @entity2 @entity0 presenting to a regional neurosurgical center (Addenbrooke's Hospital, Cambridge, UK) between 1994 and 2001. Outcome measures were clinical outcome at 6 months, number needed to treat (NNT) for favorable outcomes, and cost analysis. METHODS: Poor-grade @entity0 (World Federation of Neurological Surgeons grades 4 and 5) were transferred to the neurocritical care unit after intubation and ventilation. After resuscitation and drainage of ventricular cerebrospinal fluid for 24 hours, sedation was stopped, and @entity0 were assessed clinically. @entity0 with a Glasgow Motor Score (GMS) > or =4 underwent angiography and surgical treatment of culprit @entity1 . @entity0 with a subsequent GMS of 6 were not deemed poor grade and were discounted from the study. RESULTS: We deemed 166 ventilated @entity0 genuinely poor grade (mean age, 53.4 years; 94 @entity0 [56.6%]). Of these, 88 @entity0 (4<GMS<6; 53%) progressed to angiography and possible definitive treatment. Seventy-five @entity0 had an identifiable @entity1 , but only 64 survived for treatment. Operative mortality was 31.3%, and of the 44 survivors, 22 (34.4% of operated @entity0 ) achieved a favorable outcome. Favorable outcomes were more frequently seen in @entity0 than @entity0 (21.3% versus 6.9%) but were unrelated to @entity0 age. The NNT for 1 favorable outcome was 7 (male NNT, 15; female NNT, 5) at a cost of pound 84 336 per favorable outcome (female, pound 60 240; male, pound 180 720). CONCLUSIONS: Poor-grade @entity2 is associated with a high mortality but a significant subset of @entity0 can achieve favorable outcomes.

title: Cost-effective outcome for treating poor-grade XXXX .

answer: @entity2


abstract: @entity1 are an ideal indication for the laparoscopic surgical approach as they are basically benign diseases not requiring lymphadenectomy and extended mesenteric excision; well-established surgical procedures are available for the conventional approach. Inflammatory alterations and fragility of the bowel and mesentery, however, may demand a high level of laparoscopic experience. A broad spectrum of operations from the rather easy @entity2 ( @entity2 ) to restorative proctocolectomies for @entity3 ( @entity3 ) may be managed laparoscopically. The current evidence base for the use of laparoscopic techniques in the surgical therapy of @entity1 is presented. @entity2 limited to the terminal ileum has become a common indication for laparoscopic surgical therapy. In severe anal @entity2 , laparoscopic stoma formation is a standard procedure with low morbidity and short operative time. Studies comparing conventional and laparoscopic bowel resections, have found shorter times to first @entity6 and shorter hospital stays as well as lower complication rates in favour of the laparoscopic approach. Even complicated cases with previous surgery, abscess formation and enteric @entity7 may be operated on laparoscopically with a low morbidity. In @entity3 , restorative proctocolectomy is the standard procedure in elective surgery. The demanding laparoscopic approach is increasingly used, however, mainly in major centers; its feasibility has been proven in various studies. An increased body mass index and acute @entity4 of the bowel may be relative contraindications. Short and long-term outcomes like quality of life seem to be equivalent for open and laparoscopic surgery. Multiple studies have proven that the laparoscopic approach to @entity2 and @entity3 is a safe and successful alternative for selected @entity0 . The appropriate selection criteria are still under investigation. Technical considerations are playing an important role for the @entity5 .

title: Recent results of laparoscopic surgery in XXXX .

answer: @entity1


abstract: INTRODUCTION: The incidence and prevalence of treated @entity5 ( @entity7 ) @entity0 continue to grow throughout the world. Renal transplantation remains the preferred form of renal substitutive therapy, but given the limited number of donors, dialytic therapies are the most common modalities. OBJECTIVES: To assess a registry of @entity0 admitted for renal substitutive therapy at a single centre from 1984 to 2009. METHODS: This is a retrospective epidemiological study. The following were analyzed: demographic and clinical characteristics; incidence of @entity7 ; underlying @entity1 ; dialysis modalities; mortality; and causes of @entity4 . The variables were compared by using the chi-square test, Student t test, ANOVA, and Tukey test. Kaplan-Meier curves were used to estimate @entity0 's survival. A p value < 0.05 was considered statistically significant. RESULTS: In the period studied, 878 @entity0 were admitted to dialysis. Their mean age was 47.0    16.2 years, 549 (62.5%) were males, and 712 (81.1%) were white. The major cause of @entity7 was @entity3 in 351 (40.0%) @entity0 , @entity8 in 174 (19.8%), and chronic @entity6 in 180 (20.5%) @entity0 . The main dialytic modality was hemodialysis. The one-year mortality rate was 10.4%. The most common cause of @entity4 was cardiovascular, affecting 126 (34.6%) @entity0 . CONCLUSIONS: The cohort of @entity0 studied had a low mortality rate. @entity2 remains the most common cause of @entity5 . Screening for @entity2 is highly recommended for those @entity0 .

title: [Epidemiological study of XXXX in western Paran  . An experience of 878 cases in 25 years].

answer: @entity5


abstract: OBJECTIVE: The aim of the present work was to evaluate the anxiolytic effect of an ethanolic extract of @entity3 Linn. in @entity0 . MATERIALS AND METHODS: The elevated plus maze test (EPMT), light and dark test (L and DT) and open field test (OFT) were used to assess the anxiolytic activity of the ethanolic extract of @entity3 Linn. in @entity0 . In addition, aggressive @entity1 was also assessed by @entity1 ( @entity1 ) and rota rod test (RRT). @entity2 1 mg/kg served as a standard anxiolytic drug, administered orally. RESULTS: The ethanolic extract of @entity3 (100 and 200 mg/kg, p.o.) significantly increased the percentage of time spent and number of entries in open arm in EPMT. In L and DT, the extract produced significant increase in time spent, number of crossing and decrease in the duration of immobility in light box. In OFT, the extract showed significant increase in number of rearings, assisted rearings and number of square crossed, all of which are demonstrations of exploratory behavior. In @entity1 , @entity3 extract attenuated @entity1 related to anxiolytic activity, such as number of vocalization, leaps, rearing, biting/attacks and facing each other in paired @entity0 . Furthermore, the extract produced skeletal muscle relaxant effect assessed by RRT. CONCLUSION: The results of the present study suggest that an ethanolic extract of @entity3 may possess anxiolytic activity and provide a scientific evidence for its traditional claim.

title: Anxiolytic activity of XXXX Linn. in @entity0 as experimental models of anxiety.

answer: @entity3


abstract: OBJECTIVE: The aim of the present work was to evaluate the anxiolytic effect of an ethanolic extract of @entity3 Linn. in @entity0 . MATERIALS AND METHODS: The elevated plus maze test (EPMT), light and dark test (L and DT) and open field test (OFT) were used to assess the anxiolytic activity of the ethanolic extract of @entity3 Linn. in @entity0 . In addition, aggressive @entity1 was also assessed by @entity1 ( @entity1 ) and rota rod test (RRT). @entity2 1 mg/kg served as a standard anxiolytic drug, administered orally. RESULTS: The ethanolic extract of @entity3 (100 and 200 mg/kg, p.o.) significantly increased the percentage of time spent and number of entries in open arm in EPMT. In L and DT, the extract produced significant increase in time spent, number of crossing and decrease in the duration of immobility in light box. In OFT, the extract showed significant increase in number of rearings, assisted rearings and number of square crossed, all of which are demonstrations of exploratory behavior. In @entity1 , @entity3 extract attenuated @entity1 related to anxiolytic activity, such as number of vocalization, leaps, rearing, biting/attacks and facing each other in paired @entity0 . Furthermore, the extract produced skeletal muscle relaxant effect assessed by RRT. CONCLUSION: The results of the present study suggest that an ethanolic extract of @entity3 may possess anxiolytic activity and provide a scientific evidence for its traditional claim.

title: Anxiolytic activity of @entity3 Linn. in XXXX as experimental models of anxiety.

answer: @entity0


abstract: BACKGROUND: Balanced forces around the hip joint are critical for normal development of the hip joint, so it should be considered in every hip reconstructive procedure. METHODS: In seven @entity0 with complete destruction of the femoral head and neck due to @entity4 , a reconstructive hip surgery was done to reconstruct the femoral head without sacrificing the greater trochanter and its muscles completely. The technique consists of a modified greater trochanter arthroplasty with only a medial portion of the greater trochanter and a @entity2 . RESULTS: The average age of the @entity0 at surgery was 17  months (range 8-36  months) and the @entity0 were followed for an average of 16.6  years (range 10.9-20.1  years). The average number of second operative procedures for each @entity0 was 2 (range 1-4). The follow-up evaluation for each @entity0 included documentation of @entity1 , hip range of motion, and assessment of gait. In addition, the current @entity3 , final coverage and stability of the hip joint were documented. At final evaluation, all @entity0 had a @entity1 -free stable hip and two @entity0 had near-normal hip range of motion. All @entity0 have had satisfactory surgery results. CONCLUSIONS: By this kind of hip reconstruction, we could provide a stable painless hip joint with special attention to the greater trochanter's role on hip biomechanics.

title: Greater trochanteric preserving hip arthroplasty in the treatment of XXXX : long-term results.

answer: @entity4


abstract: OBJECTIVE: The aim of this study was to analyze the transaxillary surgical approach and results of thoracic outlet cases in our clinic in the light of the recent literature data. METHODS: Between 1996 and 2002 a series of 35 cases diagnosed as @entity3 ( @entity3 ) hospitalized and surgically treated in our clinic have been studied retrospectively. RESULTS: Twenty-six of our cases were females (75%) and the mean age was 25+/-1 (17-40 years). The most important symptom was @entity1 in the arm. In 90% of the cases the Adson, hyperabduction and abduction external rotation (AER) tests were positive. There was paresthesia in 30 cases (85%), @entity2 in 3 cases (10%), and @entity4 in 6 cases (20%). Preoperative electromyogram (EMG) was demonstrated as 56.7 m/s (50-65) and postoperative EMG was demonstrated as 65.1 m/s (60-71). Postoperative EMG values were significantly higher than the preoperative EMG values (p<0.001). All @entity0 were operated using the transaxillary approach. A total number of 40 operations were performed. Upon radiological investigation (n=17) 50% of the @entity0 were found to have cervical ribs. In 30 cases (85%) the results were very good and in four cases (12%) good, and in one case (3%) the results were bad. There was no recurrence and reoperation in the long term follow-up. CONCLUSION: Careful @entity0 history and physical examination should be done by a team, which consists of thoracic surgeon, physical therapy specialist, and a neurologist. Total resection of the first-rib with periosteally should be preferred in all of these cases with accompanying pathologies such as @entity5 , fibrous ligaments, and scalenius muscles. The transaxillary approach has provided a good exposure for the resection of cervical ribs, the first-rib and excision of fibrous ligaments and scalenius muscle by a perfect cosmetic result. All the @entity0 should be encouraged for 2 months of physical exercises starting from early postoperative period.

title: Transaxillary approach in XXXX : the importance of resection of the first-rib.

answer: @entity3


abstract: BACKGROUND: Combining systemic agents with phototherapy is becoming a standard of care for @entity0 with moderate to severe @entity1 . The combination of adalimumab and phototherapy has not been previously explored. METHODS: In this 24-week single-arm open-label study, adults with moderate to severe @entity1 received adalimumab 40 mg every other week and narrowband (NB)-UVB phototherapy three times a week for 12 weeks and then were followed for 12 weeks without treatment. Response to therapy was determined using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA) affected and Physician's Global Assessment ( @entity2 ) of @entity1 . RESULTS: Twenty @entity0 were enrolled with mean baseline scores of 17.0 for PASI, 21.2 for BSA and 3.5 for @entity2 . Half (10/20) of the @entity0 achieved PASI 75 response by week 4. At the end of treatment at week 12, 19 (95%) @entity0 achieved PASI-75, 15 (75%) @entity0 achieved PASI-90 and 11 (55%) @entity0 achieved PASI-100. Seventeen (85%) @entity0 were clear or almost clear ( @entity2 score =1). Mean baseline PASI, BSA and @entity2 scores improved by 95 percent, 93 percent and 80 percent, respectively. Disease improvement was observed through the end of follow up period at week 24. No serious adverse events were noted. CONCLUSION: Concurrent use of adalimumab and NB-UVB phototherapy was clinically effective and well tolerated in @entity0 with moderate to severe @entity1 . This combination regimen represents a new treatment option for clinical practice and warrants further investigation in controlled clinical trials.

title: Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe XXXX .

answer: @entity1